Navigation Links
GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission

SEATTLE, Oct. 3, 2011 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) announces today that GlaxoSmithKline (GSK) Biologicals Hamilton has donated a broad range of instrumentation and equipment that will assist IDRI as it designs and validates solutions to reduce the burden of disease in the developing world. IDRI will apply the gift as it prepares for clinical trials in the areas of tuberculosis, leishmaniasis, malaria, leprosy, and pandemic influenza.

"We at IDRI view this generous gift by our friends at GSK as a demonstration of confidence that the products IDRI is researching today will soon be making a difference for people worldwide," said H. Stewart Parker, IDRI's Chief Executive Officer.  "GSK's generous donation will enable new health technologies to be deployed for a number of diseases that particularly affect those in low resource settings."

"GSK has seen IDRI's talented scientists develop world-class technologies that have entered into numerous successful clinical trials," said Pamela Sager, Business Support Manager at GSK.  "We believe that the equipment we are giving to IDRI will not only further the world's scientific understanding of infectious diseases, but that this gift will also advance IDRI's global health mission."

GSK acquired the equipment when the company purchased the former Corixa site in Seattle in 2005.

About IDRI
IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities — including early stage drug discovery, preclinical testing, manufacturing, and clinical trials — IDRI strives to create an efficient pathway bringing scientific innovation from the laboratory to the people who need it most.

For more information, go to
IDRI Contact:, 206-381-0883

About GSK
GlaxoSmithKline:  A Leader in Vaccines
GlaxoSmithKline Biologicals (GSK Biologicals), GlaxoSmithKline's vaccines business, is one of the world's leading vaccine companies and a leader in innovation.   The company is active in the fields of vaccine research, development and production with over 30 vaccines approved for marketing around the world and 20 more in development.

For more information, go to

SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline CEO and CFO Interviewed on Q2 2011 Results
2. GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older
3. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
4. GlaxoSmithKline Confirms allis Safety Profile
5. Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
6. GlaxoSmithKline Wins Environmental Stewardship Award
7. GlaxoSmithKline 15th Annual IMPACT Awards Seek Philadelphia Area and Camden Healthcare Nonprofits
8. GlaxoSmithKline Applauds North Carolinas Child Advocates
9. A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products
10. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
11. GlaxoSmithKline CEO Interviewed On Half-Year and Q2 Results
Post Your Comments:
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... An inventor, from Hopkinsville, Ky., thought there ... home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. provides ... so, it could help to prevent potential overdose situations. As a result, it ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
Breaking Medicine News(10 mins):